Posted by Michael Wonder on 05 Sep 2017
CADTH publishes final outcome for Opdivo for head and neck cancer
5 September 2017 - CADTH has completed its assessment of nivolumab for the treatment of adults with recurrent or metastatic squamous cell cancer of the head and neck after platinum-based therapy.
The ERC has recommended the recommended the reimbursement of nivolumab conditional upon its cost-effectiveness being improved to an acceptable level.
Reimbursement should be for those who either have a recurrence in the first six months of potentially curative platinum-based chemotherapy or recurrence after platinum-based chemotherapy in a non-curative setting, and who have a good performance status.
